Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + anlotinib + tegafur/gimeracil/oteracil in advanced esophageal squamous cell carcinoma (post-PD-1/PD-L1)
ChiCTR2500107044Phase 2Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab, anlotinib and tegafur + gimeracil + oteracil in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong First Medical University. Primary endpoints: Progression-free survival (PFS) and Safety and tolerability. Started Aug 2025; status: recruiting.
02
Drugs
serplulimabanlotinibtegafur + gimeracil + oteracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500107044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107044.